Showcases Stock ranks Forex

Provention Bio Inc (PRVB)
4.67  0.26 (5.9%) 08-08 16:00
Open: 4.53 Pre. Close: 4.41
High: 4.709 Low: 4.5
Volume: 740,315 Market Cap: 381M
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 4.713 - 4.727 4.727 - 4.742
Low: 4.458 - 4.475 4.475 - 4.494
Close: 4.64 - 4.666 4.666 - 4.695
Stock Technical Analysis
Target: Six months: 5.59
One year: 6.53
Support: Support1: 4.09
Support2: 3.65
Resistance: Resistance1: 4.79
Resistance2: 5.59
Pivot: 4.07
Moving Averages: MA(5): 4.25
MA(20): 4.16
MA(100): 4.83
MA(250): 5.62
MACD: MACD(12,26): 0.03
Signal(12,26,9): -0.03
%K %D: %K(14,3): 78.44
%D(3): 58.56
RSI: RSI(14): 63.69
52-Week: High: 8.04
Low: 3.185
Change(%): -22.4
Average Vol(K): 3-Month: 584
10-Days: 594
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ PRVB ] has closed Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 07 Aug 2022
Provention Bio (NASDAQ:PRVB) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Sat, 06 Aug 2022
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Thu, 04 Aug 2022
Provention Bio Q2 Loss Per Share $0.46 - - CML News

Thu, 04 Aug 2022
Provention Bio Inc. Tops Q2 EPS by 4c By -

Sat, 30 Jul 2022
Provention Bio (PRVB) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Thu, 28 Jul 2022
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022 - Citizentribune

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 63.37
% Held by Insiders 43390000.00
% Held by Institutions 15.68
Shares Short (K) 4140
Shares Short Prior Month (K)
Stock Financials
EPS -111740000.000
Book Value (p.s.)
Profit Margin
Operating Margin -5.00
Return on Assets (ttm) 680.6
Return on Equity (ttm) -41.7
Qtrly Rev. Growth 1980000.0
Gross Profit (p.s.)
Sales Per Share -28.538
EBITDA (p.s.) -26041986.000
Qtrly Earnings Growth -1.97
Operating Cash Flow (M)
Levered Free Cash Flow (M) -93.93
Stock Valuation
PE Ratio
PEG Ratio
Price to Book value
Price to Sales -0.16
Price to Cash Flow 5.77
Stock Dividends
Dividend Yield
Dividend Growth 3840000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android